Equities researchers at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a research report issued on Monday. The firm set a “hold” rating on the medical research company’s stock.
Enzo Biochem Price Performance
NYSE:ENZ opened at $1.05 on Monday. Enzo Biochem has a fifty-two week low of $0.93 and a fifty-two week high of $1.50. The business has a 50 day moving average price of $1.10 and a 200-day moving average price of $1.11.
Institutional Trading of Enzo Biochem
Several large investors have recently modified their holdings of ENZ. BBR Partners LLC bought a new position in Enzo Biochem during the 3rd quarter valued at approximately $112,000. Renaissance Technologies LLC increased its stake in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 64,417 shares during the period. XTX Topco Ltd raised its holdings in shares of Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 13,735 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after acquiring an additional 11,742 shares during the period. 36.90% of the stock is owned by institutional investors.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
See Also
- Five stocks we like better than Enzo Biochem
- Why is the Ex-Dividend Date Significant to Investors?
- Guidewire Software Provides Long-Awaited Buying Opportunity
- The 3 Best Blue-Chip Stocks to Buy Now
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Fast-Growing Companies That Are Still Undervalued
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.